values for the intestinal enzyme varied among species to a much greater extent. This implies that in the liver/one/ kidney/placental (nonhuman) alkaline phosphatase the structures of the binding sites for these inhibitors have been highly conserved during mammalian evolution, but there has been much greater divergence of these structures in the evolution of intestinal alkaline phosphatases.
hatases in the corresponding human tissues. In humans, three kinds of alkaline phosphatase can be sharply differentiated by these methods, one occurring in liver, bone, and kidney, one in intestine, and one in placenta. They are evidently determined by separate gene loci. In the maimals only two sorts of alkaline phosphatase were found: one, which occurs in liver, bone, kidney, and also placenta, corresponds to the human liver/bone/ kidney enzyme-and the other corresponds to the human intestinal enzyme. The findings support our earlier proposal that the expression of a distinctive type of alkaline phosphatase in human placenta is the consequence of a late evolutionary event which occurred subsequent to the divergence of the evolutionary lineage leading to humans from the various lineages leading to other mammalian species. The concentrations of the inhibitors, phenylalanine, homoarginine, phenylalanylglycylglycine, and levamisole, required to give 50% inhibition, [Iso] , of the liver/ bone/kidney/placental (nonhuman) alkaline phosphatases showed no significant variation among the species. However, the [150] values for the intestinal enzyme varied among species to a much greater extent. This implies that in the liver/one/ kidney/placental (nonhuman) alkaline phosphatase the structures of the binding sites for these inhibitors have been highly conserved during mammalian evolution, but there has been much greater divergence of these structures in the evolution of intestinal alkaline phosphatases.
At least three gene loci determine the various forms of alkaline phosphatase [ALPase; orthophosphoric-monoester phosphohydrolase (alkaline optimum), EC 3.1.3.1] that occur in human tissues: one coding for the placental form, at least one coding for the intestinal forms (adult and fetal), and at least one coding for the liver, bone, and kidney forms (1) (2) (3) (4) . These three classes of ALPase are sharply discriminated from one another by quantitative inhibition with L-phenylalanine (Phe), L-homoarginine (Har), and L-phenylalanylglycylglycine (PheGlyGly) as inhibitors and also by their thermostabilities (1, 5, 6) . In a recent study using these criteria we compared the ALPases occurring in liver and in placenta from a series of mammals with those occurring in human liver and placenta (7) . We found that in each of the animal species studied the liver and placental ALPases closely resembled each other and were also very similar to human liver ALPase, but they differed from human placental ALPase. We have now extended these studies to include bone, kidney, and intestinal ALPases from the various species. We have also extended the battery of inhibitors to include levamisole, which is a particularly potent inhibitor of liver, bone, and kidney ALPase (8, 9) .
We find that the liver, bone, kidney, and placental ALPases from the various species resemble each other and also human liver, bone, and kidney ALPases very closely, but they are sharply differentiated from and for each inhibitor was determined as described (7) . Thermostability studies were carried out at 560C and in some cases at 650C as described (7) . In each case the time required to produce 50% inactivation of the enzyme (TW0 or Tso) was determined as described (7) .
[ (8, (10) (11) (12) (13) (14) (15) . Despite differences in detailed methodology, the results obtained appear to be fully consistent with the present findings.
Relative sensitivities to inhibition with the four inhibitors used in the present study provide sharp discrimination among the three classes of enzyme. The differences in [Iso] values, on which this discrimination is based, presumably reflect structural differences in the binding site or sites for these substances on the enzyme molecules. The inhibitors act uncompetitively (9, 16, Thermostability presumably reflects overall molecular structure in some way and so it is perhaps not surprising that the Tso values should reveal significant differences among species both for the liver/bone/kidney/placental (nonhuman) ALPases and also the intestinal ALPases. However, the intestinal ALPases show a greater degree of variability among the species than the liver/bone/kidney/placental ALPases.
We have previously suggested that the three gene loci presumed to be coding for the liver/bone/kidney, intestinal, and placental ALPases in humans were in the course 6f evolution derived by successive gene duplications from a common ancestral gene (7, 15) . Subsequent to each duplication, divergence by the fixation of point mutations was presumed to have occurred, thus accounting for the differences in specific characteristics, such as relative sensitivity to particular inhibitors, that we now observe among the enzyme products of the different loci. The remarkable differences between human placental ALPase and the ALPases present in placentas of various animal species led to the further hypothesis that the duplication from which the gene locus coding for human placental ALPase originated was a late evolutionary event that occurred subsequent to the divergence of the evolutionary lineage leading to humans from the various lineages leading to other mammalian species. An alternative hypothesis is that the gene locus for human placental ALPase does exist in these other mammalian species, but is not expressed in their placentas or indeed in other tissues so far examined so that the late evolutionary event would have involved its derepression or activation leading to its expression in placenta (7) . Whatever the nature of the evolutionary change that gave rise to the appearance of human placental ALPase, it will be of obvious interest to attempt to date the time when it first appeared by investigating the ALPases in placenta and other tissues of various primates. It has already been reported that in chimpanzees and orangutans, the placental ALPase is similar to human-type placental ALPase (18) . We have confirmed this result by thermostability, inhibition, and immunochemical studies. Our preliminary results suggest, however, that in gibbons as well as in various other less closely related primates the ALPase expressed in placenta is of the liver/bone/kidney type. If this is confirmed by further work, it suggests that the critical evolutionary event resulting in the appearance of human-type placental ALPase occurred subsequent to the divergence of the evolutionary lineage leading to the Hylobatidae (lesser apes), but prior to the divergence of the lineage leading to the Pongidae (greater apes).
